Neil Osheroff
Impact in
- Toxicology top 0.01%
- Bioactive Compounds and Antitumor Agents
- Molecular Medicine top 0.2%
Papers in
- Toxicology 58
- Bioactive Compounds and Antitumor Agents 58
-
- Cancer therapeutics and mechanisms 195
- DNA and Nucleic Acid Chemistry 43
- Synthesis and bioactivity of alkaloids 30
- Co-authors
- Robert J. KernsKatie J. AldredJoseph E. DeweeseStacie J. Froelich-AmmonJohn M. FortuneD. Andrew BurdenLynn ZechiedrichA. Kathleen McClendon
- Journals
- Biochemistry (59 papers)Journal of Biological Chemistry (49 papers)Nucleic Acids Research (13 papers)ACS Infectious Diseases (9 papers)Chemical Research in Toxicology (9 papers)
- Partner nations
- United StatesUnited KingdomDenmark
In The Last Decade
Neil Osheroff
234 papers receiving 15.0k citations
Hit Papers
Peers
Comparison fields: 5 of 165
- Toxicology 2.7k
- Molecular Medicine 1.2k
- Molecular Biology 12.7k
- Oncology 3.9k
- Organic Chemistry 2.8k
Countries citing papers authored by Neil Osheroff
This map shows the geographic impact of Neil Osheroff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Osheroff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Osheroff more than expected).
Fields of papers citing papers by Neil Osheroff
This network shows the impact of papers produced by Neil Osheroff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Osheroff. The network helps show where Neil Osheroff may publish in the future.
Co-authors
The 25 scholars most cited alongside Neil Osheroff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2023 | 5 | |
| 4 | 2023 | 7 | |
| 5 | 2022 | 21 | |
| 6 | 2019 | 13 | |
| 7 | 2019 | 9 | |
| 8 | 2017 | 18 | |
| 9 | 2017 | 43 | |
| 10 | 2017 | 79 | |
| 11 | 2016 | 32 | |
| 12 | 2013 | 127 | |
| 13 | 2011 | 30 | |
| 14 | 2010 | 8 | |
| 15 | 2010 | 22 | |
| 16 | The phase I clinical compound SNS-595 acts during S-phase and causes a sustained G2 arrest | 2005 | 1 |
| 17 | DNA topology and enzymes | 1999 | 8 |
| 18 | 1998 | 57 | |
| 19 | 1995 | 10 | |
| 20 | 1994 | 32 |
About Neil Osheroff
Neil Osheroff is a scholar working on Toxicology, Molecular Biology, Molecular Medicine, Oncology and Pharmacology, having authored 235 papers that have together received 15.3k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (195 papers), Bioactive Compounds and Antitumor Agents (58 papers), DNA and Nucleic Acid Chemistry (43 papers), Lung Cancer Research Studies (31 papers), Antibiotics Pharmacokinetics and Efficacy (30 papers), Synthesis and bioactivity of alkaloids (30 papers), Synthesis and Biological Evaluation (23 papers) and Neutropenia and Cancer Infections (23 papers). The work is most often cited by research in Toxicology (2.7k citations), Molecular Medicine (1.2k citations), Molecular Biology (12.7k citations), Oncology (3.9k citations) and Organic Chemistry (2.8k citations). Neil Osheroff has collaborated with scholars based in United States, United Kingdom and Denmark. Frequent co-authors include Robert J. Kerns, Katie J. Aldred, Joseph E. Deweese, Stacie J. Froelich-Ammon, John M. Fortune, D. Andrew Burden, Lynn Zechiedrich, A. Kathleen McClendon, Enoch P. Baldwin and Paul S. Kingma. Their work appears in journals such as Biochemistry, Journal of Biological Chemistry, Nucleic Acids Research, ACS Infectious Diseases and Chemical Research in Toxicology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.